· investment-strategies · 3 min read
Boston & Cambridge Startups We Cover in 2026: Biotech, AI Biology, and Hard Tech
As of July 2026, directory companies we can honestly place in Boston–Cambridge or Greater Boston — plus related biotech coverage tied to Boston capital with HQ labeled elsewhere.
Short answer (as of July 2026): In our startup directory, companies we can honestly place in Boston–Cambridge or Greater Boston include Boston Metal (Woburn), Boltz (Boston / MIT-origin), Ventus Therapeutics (Waltham), ROME Therapeutics (Boston), IDRx (Plymouth), GC Therapeutics (Cambridge), Curie.Bio (Boston), Alpha-9 Oncology (Boston; Vancouver ops), Anagram Therapeutics (Natick), Nava Therapeutics (Cambridge), and Mentari Therapeutics (Waltham). Other biotech IDs we track are filed below as related / HQ elsewhere — useful if you follow Boston capital, not as local HQs.
Fund shortlist: Boston–Cambridge VC firms 2026. Ecosystem dollars/themes: Boston biotech dominance playbook. Hard-tech deep dive: Boston Metal $75M. All funds: /directory.
Boston–Cambridge & Greater Boston — startups we cover
HQ notes use public citations (company sites, CB Insights, press) because most startup JSON files omit an hq field. Where we say “commonly cited,” that is intentional.
| Startup | One-liner | Stage / status | HQ evidence | Notable investors (directory) | Profile |
|---|---|---|---|---|---|
| Boston Metal | Molten Oxide Electrolysis for lower-emission critical metals / steel pathways | Other / private; $75M deploy raise (May 2026 coverage) | Woburn, MA (Greater Boston) | Not fully mapped on startup JSON; see funding note | /startup/boston-metal |
| Boltz | MIT-origin PBC applying open AI protein / biomolecular models to lab use | Seed / private | Boston / Cambridge (MIT Jameel Clinic origin) | Andreessen Horowitz | /startup/boltz |
| Ventus Therapeutics | Structure-based small-molecule discovery (ReSOLVE) | Growth / private | Waltham, MA | Andreessen Horowitz | /startup/ventus-therapeutics |
| ROME Therapeutics | Repeatome biology for cancer / autoimmune targets | Series B / private (press: acquired by Pretzel Therapeutics Jan 2026) | Boston, MA | Andreessen Horowitz, ARCH Venture Partners | /startup/rome-therapeutics |
| IDRx | Precision oncology (KIT / GIST focus in public materials) | Acquired (GSK deal in public coverage) | Plymouth, MA (Boston-area; Cambridge presence cited) | Andreessen Horowitz | /startup/idrx |
| GC Therapeutics | iPSC programming (TFome) for scalable cell therapy — Church-lab origin | Series A / private | Cambridge, MA | Andreessen Horowitz, Pear VC | /startup/gc-therapeutics |
| Curie.Bio | Hybrid seed vehicle + drug-discovery ops for pre–Series A therapeutics | Other / private (platform) | Boston, MA | Andreessen Horowitz, ARCH Venture Partners | /startup/curiebio |
| Alpha-9 Oncology | Clinical-stage targeted radiopharmaceuticals | Growth / private | Boston, MA HQ commonly cited; Vancouver ops | Andreessen Horowitz, General Catalyst | /startup/alpha-9-oncology |
| Anagram Therapeutics | Oral enzyme / malabsorption therapeutics (directory cites large 2026 raise) | Other / private | Natick, MA (MetroWest) | Investor list thin on JSON — treat as coverage stub for syndicate detail | /startup/anagram-therapeutics |
| Nava Therapeutics | Next-gen LNP delivery systems | Series A / private | Cambridge, MA | Andreessen Horowitz, F-Prime Capital | /startup/nava-therapeutics |
| Mentari Therapeutics | Anti-PACAP / CGRP migraine biologics | Growth / private | Waltham, MA | Andreessen Horowitz | /startup/mentari-therapeutics |
How to read this coverage
- Directory map of companies we index with Boston–Cambridge evidence — not a “top startups” ranking (no invented valuations).
- Biotech-skewed because that is what we have ingested; Boston SaaS/cyber names are mostly still coverage gaps.
- Status matters: IDRx is acquired; ROME has acquisition press — useful as cluster evidence, not active raise targets.
Related directory biotech — HQ elsewhere
Same /startup/ IDs, often sharing syndicates with Boston-active capital (a16z Bio, ARCH). Not claimed as local HQs.
| Startup | HQ / label | Profile |
|---|---|---|
| Hera — AI senior-care coordination | New York, NY (BCV has a Boston office; company is NYC) | /startup/hera |
| Gate Bioscience — Molecular Gate medicines | Brisbane, CA | /startup/gate-bioscience |
| Cartography Biosciences — antigen atlas / IO | SF Bay (commonly cited) | /startup/cartography-biosciences |
| Ona Therapeutics — ADCs for resistant cancers | Barcelona | /startup/ona-therapeutics |
| Rezo Therapeutics — disease-network mapping | San Francisco (UCSF-origin) | /startup/rezo-therapeutics |
| Ollin Bio — retinal biologics | Austin, TX | /startup/ollin-bio |
| Mana Bio — ML LNPs | HQ not verified as Boston | /startup/mana-bio |
| Inceptive — AI-designed mRNA | Bay Area commonly cited | /startup/inceptive |
| Patch Biosciences, Phylo, Santa Ana Bio, Orchestra Bio | HQ unclear / stubs — gap, not a city claim | linked IDs |
Coverage gaps
- Flagship-class creation companies named in the playbook without matching
/startup/pages here - Classic Boston B2B SaaS / cyber under-indexed vs biotech
- Thin investor graphs on some local names (e.g. Anagram)
Next steps
Sources
- Startup profiles linked above
- HQ corroboration: Boston Metal/Woburn; Boltz MIT/Boston; Ventus Waltham; ROME Boston; IDRx Plymouth; GCTx Cambridge; Curie.Bio Boston; Alpha-9 Boston+Vancouver; Anagram Natick; Nava Cambridge; Mentari Waltham; Gate Brisbane CA; Ona Barcelona; Ollin Austin; Hera NYC
- Boston Metal funding note · biotech playbook
- boston
- cambridge
- venture-capital
- +2 more